MedPath

Telsar Pharma, Inc.

🇺🇸United States
Ownership
Subsidiary
Established
2012-01-01
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis

Phase 2
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: Placebo
First Posted Date
2012-06-05
Last Posted Date
2016-09-28
Lead Sponsor
Telsar Pharma Inc.
Target Recruit Count
112
Registration Number
NCT01612039

A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis

Phase 1
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: Placebo
First Posted Date
2011-03-22
Last Posted Date
2012-07-24
Lead Sponsor
Telsar Pharma Inc.
Target Recruit Count
16
Registration Number
NCT01320332
Locations
🇺🇸

Advanced Clinical Research Institute, Anaheim, California, United States

🇺🇸

SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States

🇺🇸

Clinical Trials of Texas, Inc., San Antonio, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.